Articles tagged with Cancer Patients
Researchers found that regorafenib synergizes with TAS102 to inhibit cancer growth, angiogenesis, and microvessel density in preclinical models of colorectal and gastric cancers. The combination also suppresses ERK1/2 activation regardless of KRAS or BRAF mutational status.
Mayo Clinic's surgical team successfully performed the rare procedure, which included multiple organs, on a Massachusetts man with a rare form of laryngeal cancer. The landmark surgery, conducted as part of a clinical trial, marks a significant step towards making larynx transplantation available to a wider population.
The study confirms the effectiveness of 12 standards in reducing hospital length of stay, costs, and complication rates. Standardized care protocols across multiple phases of surgical care lead to improved patient outcomes and hospital efficiency.
Researchers identified two risk factors that indicate higher risk of aggressive prostate cancer, including high PSA levels and positive biopsy samples. Patients with these indicators are at increased risk of adverse pathology, early recurrence, and death.
Patients with mantle cell lymphoma are more vulnerable to other diseases and infections due to intensive chemotherapy and a weakened immune system. A large-scale national study found that MCL patients had twice as many infections as reference subjects, with common causes including influenza and urinary tract infections.
Dr. Sanaz Memarzadeh and her team aim to improve treatment outcomes for patients with platinum-resistant ovarian cancer using adoptive T-cell therapy and natural killer cells. They hope to identify new targets and biomarkers for effective treatments.
A new study has identified specific RNAs that may help identify stage II colon cancer patients who are likely to benefit from chemotherapy following surgery. The researchers found that certain housekeeping RNAs were up-regulated in patients with recurrence, suggesting their potential role in the metastatic process.
Researchers found GLP-1 receptor agonists lower risks of certain obesity-associated cancers in patients with type 2 diabetes, suggesting potential benefits for cancer prevention in high-risk populations. The study provides preliminary evidence supporting further preclinical and clinical studies to prevent specific obesity-linked cancers.
A new Finnish study from University of Turku shows that already a 30-minute exercise can increase the proportion of tumor-killing white blood cells in the bloodstream of breast cancer patients. The amount of several different white blood cell types increased during exercise, with cytotoxic T cells and natural killer cells rising the most.
A new survey study of cancer care facilities accredited by the American College of Surgeons found that most institutions have survivorship services available to their patients. However, only a minority of patients receive access to specialized fertility and sexual health services, highlighting gaps in current care.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have received a $1.8 million grant to advance personalized cancer therapy for prostate cancer patients. They aim to predict and prevent long-term side effects from radiation treatment, improving quality of life for men diagnosed with the disease.
Researchers developed engineered plasma B cells that produce large quantities of bispecific antibodies to target leukemia. These cells demonstrated sustained antitumor activity comparable to blinatumomab and may provide a long-term solution for cancer treatment.
African American woman breast cancer survivor talking about her experience with breast cancer and the impact of breast cancer on women's lives. The American Cancer Society is a leading organization in cancer research, patient services, and advocacy.
A new liquid biopsy method analyzes gene fragments in the bloodstream to detect and track cancer, enabling oncologists to tailor treatment approaches to individual patients. This non-invasive test can help monitor treatment success, detect cancer recurrence, and improve patient quality of life.
Scientists have developed a new immunotherapy that can identify and fight cancer cells in patients with Merkel cell carcinoma. The treatment involves stimulating the immune system's T cells against specific elements of the virus involved in cancer formation.
A new Europe-wide clinical framework aims to collect high-quality biological samples from patients, enabling researchers and clinicians to understand the genetic, biological, and other factors involved in childhood bone cancer. This will guide the development of tailored treatments for each patient's cancer type.
Researchers explore the feasibility of deep learning models in segmenting lesions on PET/CT images to improve salvage radiation therapy planning for prostate cancer. The study demonstrates promising potential to reduce inter- and intra-observer variations, leading to more accurate treatment outcomes.
A recent study published in JAMA found that transgender women on hormone therapy have drastically lower PSA levels, which may lead to delayed diagnosis and treatment of prostate cancer. The researchers analyzed Veterans Health Administration records and recommended caution when interpreting PSA values in transgender women.
A study found that patients with treatment-refractory cancers who received protocol exemptions to participate in a large basket/umbrella oncology trial experienced similar rates of clinical benefit and adverse events as patients who participated in the trial without waivers. The results suggest that broadening eligibility criteria for ...
A new AI-powered approach identifies a distinct subset of endometrial cancer with poorer survival rates, but would otherwise go unrecognized. The discovery will help doctors identify patients at high risk of recurrence and death, enabling more comprehensive treatment.
A new biomarker has been discovered that can help predict which patients with clear cell renal cancer are at higher risk of recurrence. The 15-gene signature was found to be independently associated with worse disease-free survival and disease-specific survival in two large validation datasets.
A novel inhibitor HVH-2930 targeting heat shock protein 90 (HSP90) demonstrates efficacy against drug-resistant breast cancer cells. It selectively downregulates HER2 signaling, crucial for breast cancer progression, without triggering the heat shock response.
Researchers have developed procedures for using gold nanostars to perform more efficient, conformal, and safe laser ablations for treating brain tumors. This technique addresses limitations in traditional LITT by providing improved precision for lesions greater than 3 cm or with complex shapes.
A pooled analysis of three randomized trials found that acupuncture significantly reduced hot flashes and hormonal side effects in women with stage 0-III breast cancer. The study showed that 64% of participants experienced improvements in hot flashes, and acupuncture also improved quality of life.
Scientists are conducting a clinical trial to explore the use of anti-retroviral medications Ritonavir and Lopinavir as a potential treatment for brain tumors in patients with Neurofibromatosis 2. The study aims to determine if these drugs can help reduce tumor growth and survival in NF2 patients.
Patients with CLL and NHL who received frequent immunoglobulin G tests had fewer infections, required fewer antimicrobial medications, and higher blood levels of IgG. Increased IgG testing is associated with a lower risk of severe infections, suggesting that clear clinician guidance may save lives.
Researchers discuss primary hepatic angiosarcoma, a rare mesenchymal liver tumor, and its poor prognosis compared to hepatocellular carcinoma. Diagnosing PHA is critical due to its similar clinical presentation to HCC.
Researchers have trained an AI model to identify DNA methylation patterns indicative of different cancer types, achieving 98.2% accuracy. This breakthrough could enable early detection and screening of cancers, leading to improved patient outcomes.
Researchers analyzed three tumor markers for associations with radiographic response and clinical outcomes in NSCLC patients. The study found that CEA, CA-125, and CA-19-9 were associated with progression and radiographic responses in NSCLC.
Researchers analyzed data from over 184,000 cancer patients to assess COVID-19 vaccine effectiveness. The study found that vaccination significantly reduces mortality and serious complications among cancer patients, especially those who received the booster dose.
Researchers identify key factors that determine when melanoma metastasizes, shedding light on optimal treatment strategies. Understanding tumor doubling time and risk assessment can help clinicians select high-risk patients who may benefit from adjuvant systemic therapy.
A subset of patients with stage 3 colon cancer who have PIK3CA mutations may benefit from celecoxib treatment, which improved overall survival and reduced disease-free survival rates. The study's findings suggest a potential personalized approach to additional therapy for patients with early-stage colon cancer.
Researchers studied cancer survivors under 25 who had cancer since 1958 and found they were three times more likely to develop cancer later in life. Socioeconomic factors also played a role in survival rates, with lower education levels and foreign backgrounds increasing risk.
A new study found that nearly five percent of pancreatic adenocarcinoma patients achieve a pathological complete response (pCR) after treatment, leading to a 63% 5-year survival rate. The research highlights the importance of tailoring treatment based on factors such as chemotherapy regimens and radiation therapy.
The American Society for Radiation Oncology (ASTRO) has published an updated clinical guideline for treating patients with HPV-related oropharyngeal squamous cell carcinoma. The guideline emphasizes the importance of tailored radiation strategies to maximize patient survival while minimizing side effects. It provides recommendations fo...
Researchers at Virginia Tech have discovered a possible new pathway to treat colorectal cancer by targeting the NF-kB-inducing kinase (NIK) protein. The study, led by Irving Coy Allen, identifies changes in a significant signaling pathway in human patients and presents potential targets for therapeutics.
A new machine-learning model using serum fusion-gene levels predicts HCC with an accuracy of 83-91%, significantly improving upon current biomarkers like serum alpha-fetal protein. This breakthrough tool may help identify patients at risk and monitor cancer recurrence, leading to improved survival rates.
A new trial indicates that immunotherapy could successfully treat the most common form of colorectal cancer. The study, published in Nature Medicine, found that botensilimab and balstilimab caused tumours to shrink or remain stable in 61% of patients with microsatellite stable metastatic colorectal cancer.
Researchers at Brigham and Women's Hospital have developed a new nanomedicine therapy that delivers anticancer drugs to lung cancer cells and enhances the immune system's ability to fight cancer. The therapy shows promising results in cancer cells in the lab and in mouse lung tumor models, with potential applications for improving care...
A phase II clinical trial found trametinib effective in treating pediatric patients with relapsed or refractory juvenile myelomonocytic leukemia (JMML), with seven of ten patients alive after two years. The treatment showed antitumor activity and downregulated inflammatory signaling, offering hope for JMML patients and their families.
Researchers at Wyss Institute develop subcutaneous scaffolds to restimulate CAR-T cells, increasing therapeutic efficacy in mice with aggressive blood tumors. The biomaterials increase CAR-T cell numbers and steer differentiation into tumor-killing T cells.
A Vanderbilt University Medical Center-led research team discovered a connection between obesity and cancer, revealing that macrophages play an unexpected role in the complicated connection. Obesity increases macrophage frequency in tumors and induces PD-1 expression, which can contribute to both increased cancer risk and enhanced resp...
Researchers at Northwestern University discovered an attenuated virus that can help eliminate cancer in mice and prevent future tumor development. The therapy works by raising 'red flags' on tumors to alert immune cells to attack them.
Researchers developed a nine-week, phone-delivered positive psychology program called PATH to improve psychological well-being in blood cancer patients. The intervention had promising effects on patient-reported outcomes, with high participation and completion rates.
A new AI model has been shown to significantly improve the accuracy of diagnosing prostate cancer by 45 times compared to doctors' measurements alone. The system assists in mapping out the boundaries of cancerous tissue, reducing the risk of underestimation and enabling more precise treatment planning and effective surgical procedures.
A novel AI approach can accurately detect six different types of cancer on whole-body PET/CT scans, automatically quantifying tumor burden. The tool provides a framework for identifying robust predictive biomarkers and enabling early detection and treatment of cancer.
Kotaro Sasaki and his team developed an in vitro seminoma model to study chromosomal anomalies and signaling pathways in testicular cancer. The model sheds light on the cellular origin of seminoma, providing new insights into its development.
[177Lu]Lu-PSMA-617 significantly improves radiographic progression-free survival and overall quality of life for patients with taxane-naive mCRPC, while minimizing adverse events. The study's findings suggest that [177Lu]Lu-PSMA-617 may change the treatment paradigm for pre-taxane advanced prostate cancer patients.
Researchers found that only 41.5% of cancer patients could successfully book a new appointment at a clinic due to various barriers, including language issues and workflow challenges.
The Association for Molecular Pathology has published guidelines for tumor mutational burden (TMB) testing, aiming to standardize calculation and reporting of TMB as a predictive biomarker for immune checkpoint inhibitor therapies. These recommendations emphasize the importance of comprehensive methodological descriptions in publications.
The University of Oklahoma has been awarded a $1.2 million grant to lead a Phase 1B clinical trial for the treatment of prostate cancer when it begins to spread beyond the prostate. The trial combines two existing drugs, relugolix and enzalutamide, which may provide more effective treatments for aggressive prostate cancer patients.
Researchers demonstrate the utility of analysing circulating tumor DNA (ctDNA) through a high-sensitivity liquid biopsy platform, allowing for early prediction of treatment response and prognosis. The study shows that detecting low levels of ctDNA can predict longer progression-free survival and overall survival.
Researchers at UC Davis Health discovered that mesalamine can replace good bacteria's work in fighting Candida albicans in the gut. The study found that mesalamine maintains a low oxygen environment that prevents fungal growth, reducing the risk of invasive candidiasis.
A Phase III trial led by the University of Texas M. D. Anderson Cancer Center found proton therapy to be non-inferior to traditional radiation therapy in treating head and neck cancer. The study revealed a significant reduction in malnutrition and feeding-tube dependency with proton therapy.
A new study by Dana-Farber Cancer Institute researchers found that telehealth can significantly reduce greenhouse gas emissions associated with cancer care. By analyzing data from a regional cancer center, the team calculated that nationwide, cancer care utilizing telehealth and local care would generate 33.1% less greenhouse gas emiss...
The first phase 1 trial of the bispecific antibody FS222 demonstrates promising antitumour activity, especially in patients with metastatic cutaneous melanoma refractory to immunotherapy. Preliminary results show partial or complete objective response rates in various tumor types.
A combination of amivantamab and lazertinib shows benefits over standard treatment in a subgroup of patients with advanced lung cancer, particularly those with poor prognostic markers. The new therapeutic strategy reduced the risk of disease progression and death by 30% compared to osimertinib.
A stepped-care model integrating palliative care at key points in patients' cancer trajectories shows reduced palliative care visits without compromising quality of life. The approach enables more efficient delivery of early palliative care, enhancing patient-reported outcomes.
A new 'armored' form of CAR T cell therapy, developed by University of Pennsylvania researchers, has shown significant responses in patients whose cancers don't respond to current CAR T cell therapies. The three-day manufacturing process also shortens treatment time for aggressive, fast-growing cancers.
Researchers at Dana-Farber Cancer Institute have reported encouraging results from three separate studies on treatments for central nervous system lymphoma, breast cancer, and glioblastoma. CAR T-cell therapy showed a 94% overall response rate in patients with CNS lymphoma, while an antibody-drug conjugate plus checkpoint inhibitor imp...